+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Human Chorionic Gonadotropin Market by Technology, Therapeutic Area, and End User - Global Opportunity Analysis and Industry Forecast, 2017-2025

  • ID: 4656181
  • Report
  • September 2018
  • Region: Global
  • 197 pages
  • Allied Analytics LLP
1 of 4
Human Chorionic Gonadotropin (hCG) Market Overview:

The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025. hCG hormone supports the normal development of an egg in a woman's ovary and stimulates the release of the egg during ovulation. It can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology. It is widely being used to treat infertility-related problems in women as well as increase sperm count in men. Moreover, it is used to treat cryptorchidism in young boys, a condition when the testicles have not dropped down into the scrotum normally.

Significant surge in infertility issues among men & women and increase in prevalence of hypogonadism in geriatric population drive the growth of the global hCG market. In addition, increase in awareness toward hCG among healthcare professionals and patients fuels the market growth. However, availability of substitutes and cautions & warnings issued by FDA against the side effects of hCG hamper the growth of the market. On the contrary, rise in popularity of fertility tourism and availability of advanced IVF facilities & treatment options are expected to provide lucrative opportunities for the market in the near future.

The global hCG market is segmented based on technology, therapeutic area, end user, and region. By technology, the market is bifurcated into natural source extraction and recombinant technology. Based on therapeutic area, it is classified into female infertility treatment, oligospermic treatment, male hypogonadism, and others. Depending on end user, it is segregated into fertility clinics, research institutions, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Human Chorionic Gonadotropin (hCG) Market:
  • The study provides an in-depth analysis of the global human chorionic gonadotropin (hCG) market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A qualitative analysis of driving factors and opportunities helps analyze the competitive scenario of the market.
  • Porter’s Five Forces analysis is provided to interpret the bargaining power of the suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.
By Technology
  • Natural Source Extraction
  • Recombinant Technology
By Therapeutic Area
  • Female Infertility Treatment
  • Male Hypogonadism
  • Oligospermic Treatment
  • Others
By End User
  • Fertility Clinics
  • Research Institutions
  • Others
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Turkey
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA
KEY MARKET PLAYERS
  • Bristol Myers Squibb Company
  • Merck & Co., Inc.
  • Ferring B.V.
  • Fresenius Kabi AG
  • Cigna
  • Sun Pharmaceutical Industries Ltd.
  • Lee BioSolutions, Inc.
  • Sanzyme
  • Scripps Laboratories
  • Lupin
The other players in the value chain include (profiles not included in the report):
  • Kamiya Biomedical Company
  • Intas Pharmaceuticals
  • Prospec-Tany Technogene Ltd.
  • Cipla Limited
  • Biocare Medical LLC
  • MyBioSource
  • Zydus Cadila
  • Life Medicare & Biotech Pvt. Ltd.
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Porters five forces analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. High risk of hypogonadism in geriatric population
3.5.1.2. Rise in infertility rates
3.5.1.3. Increase in awareness toward hCG among healthcare professionals and patients
3.5.2. Restraints
3.5.2.1. Availability of substitutes
3.5.2.2. Cautions & warnings issued by FDA against the side effects of hCG
3.5.3. Opportunity
3.5.3.1. Rise in popularity of fertility tourism

CHAPTER 4: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY
4.1. Overview
4.1.1. Market size and forecast
4.2. Natural source extraction
4.2.1. Key trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Recombinant technology
4.3.1. Key trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

CHAPTER 5: HUMAN CHORIONIC GONADOTROPIN MARKET, BY THERAPEUTIC AREA
5.1. Overview
5.1.1. Market size and forecast
5.2. Female infertility treatment
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Oligospermic treatment
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Male hypogonadism
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast
5.5.2. Market analysis, by country

CHAPTER 6: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Fertility clinics
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Research institutes
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Others
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. North America market size and forecast, by country
7.2.2.1. U.S. market size and forecast, by technology
7.2.2.2. U.S. market size and forecast, by therapeutic area
7.2.2.3. U.S. market size and forecast, by end user
7.2.2.4. Canada market size and forecast, by technology
7.2.2.5. Canada market size and forecast, by therapeutic area
7.2.2.6. Canada market size and forecast, by end user
7.2.2.7. Mexico market size and forecast, by technology
7.2.2.8. Mexico market size and forecast, by therapeutic area
7.2.2.9. Mexico market size and forecast, by end user
7.2.3. North America market size and forecast, by technology
7.2.4. North America market size and forecast, by therapeutic area
7.2.5. North America market size and forecast, by end user
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Europe market size and forecast, by country
7.3.2.1. Germany market size and forecast, by technology
7.3.2.2. Germany market size and forecast, by therapeutic area
7.3.2.3. Germany market size and forecast, by end user
7.3.2.4. UK market size and forecast, by technology
7.3.2.5. UK market size and forecast, by therapeutic area
7.3.2.6. UK market size and forecast, by end user
7.3.2.7. France market size and forecast, by technology
7.3.2.8. France market size and forecast, by therapeutic area
7.3.2.9. France market size and forecast, by end user
7.3.2.10. Rest of Europe market size and forecast, by technology
7.3.2.11. Rest of Europe market size and forecast, by therapeutic area
7.3.2.12. Rest of Europe market size and forecast, by end user
7.3.3. Europe market size and forecast, by technology
7.3.4. Europe market size and forecast, by therapeutic area
7.3.5. Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Asia-Pacific market size and forecast, by country
7.4.2.1. Japan market size and forecast, by technology
7.4.2.2. Japan market size and forecast, by therapeutic area
7.4.2.3. Japan market size and forecast, by end user
7.4.2.4. China market size and forecast, by technology
7.4.2.5. China market size and forecast, by therapeutic area
7.4.2.6. China market size and forecast, by end user
7.4.2.7. India market size and forecast, by technology
7.4.2.8. India market size and forecast, by therapeutic area
7.4.2.9. India market size and forecast, by end user
7.4.2.10. Australia market size and forecast, by technology
7.4.2.11. Australia market size and forecast, by therapeutic area
7.4.2.12. Australia market size and forecast, by end user
7.4.2.13. Rest of Asia-Pacific market size and forecast, by technology
7.4.2.14. Rest of Asia-Pacific market size and forecast, by therapeutic area
7.4.2.15. Rest of Asia-Pacific market size and forecast, by end user
7.4.3. Asia-Pacific market size and forecast, by technology
7.4.4. Asia-Pacific market size and forecast, by therapeutic area
7.4.5. Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA market size and forecast, by country
7.5.2.1. Brazil market size and forecast, by technology
7.5.2.2. Brazil market size and forecast, by therapeutic area
7.5.2.3. Brazil market size and forecast, by end user
7.5.2.4. Turkey market size and forecast, by technology
7.5.2.5. Turkey market size and forecast, by therapeutic area
7.5.2.6. Turkey market size and forecast, by end user
7.5.2.7. Saudi Arabia market size and forecast, by technology
7.5.2.8. Saudi Arabia market size and forecast, by therapeutic area
7.5.2.9. Saudi Arabia market size and forecast, by end user
7.5.2.10. South Africa market size and forecast, by technology
7.5.2.11. South Africa market size and forecast, by therapeutic area
7.5.2.12. South Africa market size and forecast, by end user
7.5.2.13. Rest of LAMEA market size and forecast, by technology
7.5.2.14. Rest of LAMEA market size and forecast, by therapeutic area
7.5.2.15. Rest of LAMEA market size and forecast, by end user
7.5.3. LAMEA market size and forecast, by technology
7.5.4. LAMEA market size and forecast, by therapeutic area
7.5.5. LAMEA market size and forecast, by end user

CHAPTER 8: COMPANY PROFILES
8.1. Bristol Myers Squibb Company
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.2. Ferring Pharmaceuticals Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. Merck & Co., Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Fresenius Kabi AG
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance
8.5. Cigna
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. Sun Pharmaceutical Industries Ltd.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Lee BioSolutions Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. Sanzyme
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.9. Scripps Laboratories
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. LUPIN
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Human Chorionic Gonadotropin (hCG) Market by Technology, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2018-2025, the global human chorionic gonadotropin (hCG) market generated revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.

Rise in incidence of infertility-related problems in both the genders drive the growth of the global hCG market. In addition, upsurge in the adoption of hCG hormone in pain management and weight loss propel the market growth. Furthermore, incorporation of recombinant technology for the development of hCG is anticipated to offer lucrative opportunities for the market growth in the near future.

Based on technology, the market is divided into natural source extraction and recombinant technology. The recombinant technology segment is expected to register the highest growth rate during the forecast period. However, the natural source extraction segment dominated the global market in 2017 and is anticipated to remain dominant throughout the forecast period. This is attributed to easy and low-cost availability of hCG from pregnant womens urine and placenta cells.

Based on the therapeutic area, the global market is classified into female infertility treatment, oligospermic treatment, male hypogonadism, and others. Male hypogonadism segment is anticipated to witness highest growth rate in the global market, owing to high susceptibility of geriatric population to hypogonadism. However, female infertility treatment dominated the therapeutic area segment in 2017, owing to surge in female infertility-related problems such as polycystic ovaries, hormonal imbalance, and others.

Key Findings of the Human Chorionic Gonadotropin (hCG) Market:

The oligospermic treatment segment registered the second highest CAGR during the forecast period among the therapeutic area.
The fertility clinics end user segment dominated the market, accounting for half of the total share in 2017.
North America dominated the market, accounting for maximum share of the overall market in 2017.
Germany was the highest contributor to the European human chorionic gonadotropin (hCG) market in 2017 and is expected to maintain this dominance throughout the forecast period.

Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to its high population base, surge in disposable income, and rise in awareness toward infertility treatment procedures. In addition, rise in fertility tourism in Asia-Pacific countries such as Thailand and Malaysia boosts the market growth.

The major companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., Ferring B.V., Fresenius Kabi AG, Cigna, Sun Pharmaceutical Industries Ltd, Lee BioSolutions Inc., Sanzyme, Scripps Laboratories, and Lupin AB. The other players operating in the global human chorionic gonadotropin (hCG) market include Kamiya Biomedical Company, Intas Pharmaceuticals, Prospec-Tany Technogene Ltd., Cipla Limited, Biocare Medical, LLC, MyBioSource, Zydus Cadila, and Life Medicare & Biotech Pvt. Ltd.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll